Buy Rating for Gain Therapeutics: Promising Phase 1b Trial and Strong Financial Position Support Positive Outlook

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Gain Therapeutics (GANX – Research Report), retaining the price target of $8.00.

Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Gain Therapeutics. The company’s lead asset, GT-02287, is progressing through a Phase 1b clinical trial aimed at evaluating its safety and tolerability in Parkinson’s disease patients. The trial’s secondary endpoints, including pharmacokinetics and biomarker levels, are expected to provide insights into the mechanism of GT-02287, potentially offering neuroprotective benefits. The favorable outcomes from a previous Phase 1 study, which demonstrated significant target engagement and a strong safety profile, further support the positive outlook for GT-02287.
Additionally, Gain Therapeutics’ financial position appears stable, with sufficient cash reserves to fund operations into late 2025. The company’s financial results for the first quarter of 2025 were in line with expectations, and the valuation model used by Selvaraju, which includes a discounted cash flow approach, supports a price target of $8 per share. Despite the inherent risks associated with clinical trials and regulatory approvals, the potential upside from successful development and commercialization of GT-02287 underpins the Buy rating.

In another report released on May 15, BTIG also maintained a Buy rating on the stock with a $10.00 price target.